Company intelligence / Profile preview

Jalon Therapeutics

Paris, Île-de-France (Paris), Francejalontx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead candidate JRT39 has shown superior preclinical efficacy, stability, and pharmacokinetic profiles. The company’s peptides block critical protein interactions inside cancer cells and induce membranolysis in tumor cells. Preclinical data suggest potential for broad anti-cancer activity with a novel mechanism of action. Clinical results are not yet available as the programs are preclinical.

Therapeutic areas: Oncology
Modalities: Peptides (molecular decoys)Targeted protein-protein interaction inhibitors
Industry: Biotech

Drug pipeline

2 assets

JRT39

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Bpifrance (funding/investment partnership)

Beyond the preview

Go deeper on Jalon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jalon Therapeutics.

Explore the full profile